{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:45:53Z","timestamp":1792590353625,"version":"4.5.0"},"reference-count":139,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Neurodegeneration with Brain Iron Accumulation (NBIA) is a heterogeneous group of progressive neurodegenerative diseases characterized by iron deposition in the globus pallidus and the substantia nigra. As of today, 15 distinct monogenetic disease entities have been identified. The four most common forms are pantothenate kinase-associated neurodegeneration (PKAN), phospholipase A2 group VI (PLA2G6)-associated neurodegeneration (PLAN), beta-propeller protein-associated neurodegeneration (BPAN) and mitochondrial membrane protein-associated neurodegeneration (MPAN). Neurodegeneration with Brain Iron Accumulation disorders present with a wide spectrum of clinical symptoms such as movement disorder signs (dystonia, parkinsonism, chorea), pyramidal involvement (e.g., spasticity), speech disorders, cognitive decline, psychomotor retardation, and ocular abnormalities. Treatment remains largely symptomatic but new drugs are in the pipeline. In this review, we discuss the rationale of new compounds, summarize results from clinical trials, provide an overview of important results in cell lines and animal models and discuss the future development of disease-modifying therapies for NBIA disorders. A general mechanistic approach for treatment of NBIA disorders is with iron chelators which bind and remove iron. Few studies investigated the effect of deferiprone in PKAN, including a recent placebo-controlled double-blind multicenter trial, demonstrating radiological improvement with reduction of iron load in the basal ganglia and a trend to slowing of disease progression. Disease-modifying strategies address the specific metabolic pathways of the affected enzyme. Such tailor-made approaches include provision of an alternative substrate (e.g., fosmetpantotenate or 4\u2032-phosphopantetheine for PKAN) in order to bypass the defective enzyme. A recent randomized controlled trial of fosmetpantotenate, however, did not show any significant benefit of the drug as compared to placebo, leading to early termination of the trials' extension phase. 4\u2032-phosphopantetheine showed promising results in animal models and a clinical study in patients is currently underway. Another approach is the activation of other enzyme isoforms using small molecules (e.g., PZ-2891 in PKAN). There are also compounds which counteract downstream cellular effects. For example, deuterated polyunsaturated fatty acids (D-PUFA) may reduce mitochondrial lipid peroxidation in PLAN. In infantile neuroaxonal dystrophy (a subtype of PLAN), desipramine may be repurposed as it blocks ceramide accumulation. Gene replacement therapy is still in a preclinical stage.<\/jats:p>","DOI":"10.3389\/fneur.2021.629414","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T12:40:06Z","timestamp":1618490406000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":70,"title":["Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders"],"prefix":"10.3389","volume":"12","author":[{"given":"Vassilena","family":"Iankova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Karin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klopstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"B1","unstructured":"Neurodegeneration With Brain Iron Accumulation2010"},{"key":"B2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/ph12010027","article-title":"Neurodegeneration with brain iron accumulation disorders: valuable models aimed at understanding the pathogenesis of iron deposition","volume":"12","author":"Levi","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1039\/c7mt00116a","article-title":"The elemental role of iron in DNA synthesis and repair","volume":"9","author":"Puig","year":"2017","journal-title":"Metallomics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.3390\/ijms13022368","article-title":"Impaired iron status in aging research","volume":"13","author":"Xu","year":"2012","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(14)70117-6","article-title":"The role of iron in brain ageing and neurodegenerative disorders","volume":"13","author":"Ward","year":"2014","journal-title":"Lancet Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1471-4159.2011.07500.x","article-title":"The role of metallobiology and amyloid-\u03b2 peptides in Alzheimer's disease","volume":"120","author":"Roberts","year":"2012","journal-title":"J Neurochem"},{"key":"B7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jtemb.2016.03.010","article-title":"Iron chelation in the treatment of neurodegenerative diseases","volume":"38","author":"Dusek","year":"2016","journal-title":"J Trace Elem Med Biol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ajhg.2018.01.003","article-title":"Impaired transferrin receptor palmitoylation and recycling in neurodegeneration with brain iron accumulation","volume":"102","author":"Drecourt","year":"2018","journal-title":"Am J Hum Genet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.hoc.2004.06.019","article-title":"Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias","volume":"18","author":"Kwiatkowski","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"B10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/asheducation-2006.1.42","article-title":"New advances in iron chelation therapy","author":"Cohen","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jhep.2010.04.039","article-title":"Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation","volume":"53","author":"Finkenstedt","year":"2010","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0300-483x(95)03301-u","article-title":"The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat","volume":"108","author":"Fredenburg","year":"1996","journal-title":"Toxicology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/s0006-2952(99)00031-3","article-title":"Investigation into the correlation between the structure of hydroxypyridinones and blood-brain barrier permeability","volume":"57","author":"Habgood","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/j.1365-2141.1994.tb04841.x","article-title":"The transport of two iron chelators, desferrioxamine B and L1, across Caco-2 monolayers","volume":"86","author":"Hamilton","year":"1994","journal-title":"Br J Haematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF00341968","article-title":"Weiterer Beitrag zur Kenntnis der Hallervorden-Spatzschen Krankheit [A further contribution to the knowledge of the Hallervorden-Spatz disease]","volume":"212","author":"Gallyas","year":"1968","journal-title":"Arch Psychiatr Nervenkr"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/mds.23751","article-title":"Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial","volume":"26","author":"Zorzi","year":"2011","journal-title":"Mov Disord"},{"key":"B17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.parkreldis.2014.03.002","article-title":"Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up","volume":"20","author":"Cossu","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"B18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S1474-4422(19)30142-5","article-title":"Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study","volume":"18","author":"Klopstock","year":"2019","journal-title":"Lancet Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3389\/fneur.2017.00385","article-title":"Patient affected by beta-propeller protein-associated neurodegeneration: a therapeutic attempt with iron chelation therapy","volume":"8","author":"Fonderico","year":"2017","journal-title":"Front Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.14802\/jmd.17082","article-title":"A patient with beta-propeller protein-associated neurodegeneration: treatment with iron chelation therapy","volume":"11","author":"Lim","year":"2018","journal-title":"J Mov Disord"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/acn3.116","article-title":"Brain iron quantification by MRI in mitochondrial membrane protein-associated neurodegeneration under iron-chelating therapy","volume":"1","author":"L\u00f6bel","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/13554794.2016.1247458","article-title":"Clinical and imaging characteristics of late onset mitochondrial membrane protein-associated neurodegeneration (MPAN)","volume":"22","author":"Gore","year":"2016","journal-title":"Neurocase"},{"key":"B23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mds.25914","article-title":"Using proteomics to assess potential biomarkers of systemic iron trafficking, inflammation and oxidative stress in a patient with PLA2G6 associated neurodegeneration (PLAN) being treated with deferiprone","volume":"29","author":"Praschberger","year":"2014","journal-title":"Mov Disord"},{"key":"B24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/brain\/awl319","article-title":"Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation","volume":"130","author":"Chinnery","year":"2007","journal-title":"Brain"},{"key":"B25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12876-020-01237-8","article-title":"New mutation of the ceruloplasmin gene in the case of a neurologically asymptomatic patient with microcytic anaemia, obesity and supposed Wilson's disease","volume":"20","author":"Ondrejkovi\u010dov\u00e1","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2169\/internalmedicine.4178-19","article-title":"Deferasirox might be effective for microcytic anemia and neurological symptoms associated with aceruloplasminemia: a case report and review of the literature","volume":"59","author":"Miyake","year":"2020","journal-title":"Intern Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/01.HS9.0000563464.25528.31","article-title":"Erytrocytapheresis in aceruloplasminemia prevents progression of cerebral iron accumulation after chelator-induced normalization of iron stores","volume":"3","author":"Van Gelder","year":"2019","journal-title":"HemaSphere"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e3594","DOI":"10.1097\/MD.0000000000003594","article-title":"Aceruloplasminemia with psychomotor excitement and neurological sign was improved by minocycline (case report)","volume":"95","author":"Hayashida","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp.2007.120568","article-title":"Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation","volume":"79","author":"Skidmore","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/hepr.12292","article-title":"Case of presymptomatic aceruloplasminemia treated with deferasirox","volume":"44","author":"Tai","year":"2014","journal-title":"Hepatol Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"389","DOI":"10.5581\/1516-8484.20110104","article-title":"Aceruloplasminemia: a rare disease\u2014diagnosis and treatment of two cases","volume":"33","author":"Roberti","year":"2011","journal-title":"Rev Bras Hematol Hemoter"},{"key":"B32","first-page":"316","article-title":"Central nervous system involvement in a rare genetic iron overload disorder","volume":"68","author":"Bethlehem","year":"2010","journal-title":"Neth J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2169\/internalmedicine.52.0102","article-title":"Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation","volume":"52","author":"Suzuki","year":"2013","journal-title":"Intern Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/cge.12145","article-title":"Novel ceruloplasmin mutation causing aceruloplasminemia with hepatic iron overload and diabetes without neurological symptoms","volume":"85","author":"Rusticeanu","year":"2014","journal-title":"Clin Genet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1055\/s-0034-1383650","article-title":"Aceruloplasminaemia: a family with a novel mutation and long-term therapy with deferasirox","volume":"47","author":"Lindner","year":"2015","journal-title":"Horm Metab Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"bcr2014207541","DOI":"10.1136\/bcr-2014-207541","article-title":"Aceruloplasminaemia: a rare but important cause of iron overload","volume":"2015","author":"Doyle","year":"2015","journal-title":"BMJ Case Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.parkreldis.2018.02.036","article-title":"Phenotypic heterogeneity in seven Italian cases of aceruloplasminemia","volume":"51","author":"Pelucchi","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"B38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.bcmd.2015.12.011","article-title":"Does aceruloplasminemia modulate iron phenotype in thalassemia intermedia?","volume":"57","author":"Pelucchi","year":"2016","journal-title":"Blood Cells Mol Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/ana.410410318","article-title":"Use of desferrioxamine in the treatment of aceruloplasminemia","volume":"41","author":"Miyajima","year":"1997","journal-title":"Ann Neurol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000008091","article-title":"A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: administration of fresh-frozen human plasma","volume":"42","author":"Yonekawa","year":"1999","journal-title":"Eur Neurol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/s0168-8278(02)00042-9","article-title":"Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights","volume":"36","author":"Lor\u00e9al","year":"2002","journal-title":"J Hepatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1136\/jnnp.2003.017434","article-title":"Clinical, molecular, and PET study of a case of aceruloplasminaemia presenting with focal cranial dyskinesia","volume":"75","author":"Haemers","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jns.2010.08.019","article-title":"Aceruloplasminemia in a Japanese woman with a novel mutation of CP gene: clinical presentations and analysis of genetic and molecular pathogenesis","volume":"298","author":"Hida","year":"2010","journal-title":"J Neurol Sci"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1002\/mds.23797","article-title":"Desferrioxamine treatment of aceruloplasminemia: long-term follow-up","volume":"26","author":"Pan","year":"2011","journal-title":"Mov Disord"},{"key":"B45","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/mds.21938","article-title":"Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability","volume":"23","author":"Fasano","year":"2008","journal-title":"Mov Disord"},{"key":"B46","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1136\/gut.2003.030429","article-title":"Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation","volume":"53","author":"Mariani","year":"2004","journal-title":"Gut"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1212\/WNL.0000000000001956","article-title":"Iron chelation therapy to prevent the manifestations of aceruloplasminemia","volume":"85","author":"Bove","year":"2015","journal-title":"Neurology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10072-016-2756-x","article-title":"Is aceruloplasminemia treatable? Combining iron chelation and fresh-frozen plasma treatment","volume":"38","author":"Poli","year":"2017","journal-title":"Neurol Sci"},{"key":"B49","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/imj.13309","article-title":"Aceruloplasminaemia: a disorder of diabetes and neurodegeneration","volume":"47","author":"Calder","year":"2017","journal-title":"Intern Med J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.braindev.2007.01.001","article-title":"Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate","volume":"29","author":"Kuhn","year":"2007","journal-title":"Brain Dev"},{"key":"B51","first-page":"663","article-title":"Hereditary caeruloplasmin deficiency, dementia and diabetes mellitus","volume":"87","author":"Logan","year":"1994","journal-title":"QJM"},{"key":"B52","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1136\/gut.47.6.858","article-title":"Hepatic iron overload in aceruloplasminaemia","volume":"47","author":"Hellman","year":"2000","journal-title":"Gut"},{"key":"B53","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/bjh.13401","article-title":"Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminaemia","volume":"171","author":"Badat","year":"2015","journal-title":"Br J Haematol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/ana.410370515","article-title":"Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family","volume":"37","author":"Morita","year":"1995","journal-title":"Ann Neurol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/jnen\/61.12.1069","article-title":"Astrocytic deformity and globular structures are characteristic of the brains of patients with aceruloplasminemia","volume":"61","author":"Kaneko","year":"2002","journal-title":"J Neuropathol Exp Neurol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/mdc3.12393","article-title":"Neurodegeneration with brain iron accumulation (NBIA) syndromes presenting with late-onset craniocervical dystonia: an illustrative case series","volume":"4","author":"Brugger","year":"2016","journal-title":"Mov Disord Clin Pract"},{"key":"B57","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jhep.2005.02.013","article-title":"Aceruloplasminemia in an asymptomatic patient with a new mutation. Diagnosis and family genetic analysis","volume":"42","author":"P\u00e9rez-Aguilar","year":"2005","journal-title":"J Hepatol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2169\/internalmedicine.50.5108","article-title":"Criteria for early identification of aceruloplasminemia","volume":"50","author":"Ogimoto","year":"2011","journal-title":"Intern Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jns.2014.02.014","article-title":"Superficial siderosis associated with aceruloplasminemia. Case report","volume":"339","author":"Matsushima","year":"2014","journal-title":"J Neurol Sci"},{"key":"B60","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.parkreldis.2018.03.003","article-title":"Aceruloplasminemia and putaminal cavitation","volume":"51","author":"Riboldi","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.4045\/tidsskr.14.1115","article-title":"A man in his 50s with high ferritin levels and increasing cognitive impairment","volume":"135","author":"Bj\u00f8rk","year":"2015","journal-title":"Tidsskr Nor Laegeforen"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.2169\/internalmedicine.9855-17","article-title":"Aceruloplasminemia with abnormal compound heterozygous mutations developed neurological dysfunction during phlebotomy therapy","volume":"57","author":"Watanabe","year":"2018","journal-title":"Intern Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"894","DOI":"10.7326\/L17-0621","article-title":"Peripheral neuropathy and the ceruloplasmin gene","volume":"168","author":"Hines","year":"2018","journal-title":"Ann Intern Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/dme.12712","article-title":"Aceruloplasminemia presents as type 1 diabetes in non-obese adults: a detailed case series","volume":"32","author":"Vroegindeweij","year":"2015","journal-title":"Diabet Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.parkreldis.2016.12.010","article-title":"New insights in the neurological phenotype of aceruloplasminemia in Caucasian patients","volume":"36","author":"Vroegindeweij","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"B66","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13023-020-01385-w","article-title":"Effects of iron chelation therapy on the clinical course of aceruloplasminemia: an analysis of aggregated case reports","volume":"15","author":"Vroegindeweij","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B67","unstructured":"Overview of Malaria Treatment2018"},{"key":"B68","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s13659-018-0162-1","article-title":"Antitumor research on artemisinin and its bioactive derivatives","volume":"8","author":"Zhang","year":"2018","journal-title":"Nat Prod Bioprospect"},{"key":"B69","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-018-0561-0","article-title":"Artesunate shows potent anti-tumor activity in B-cell lymphoma","volume":"11","author":"V\u00e5tsveen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"988","DOI":"10.2174\/1568009618666180425142653","article-title":"The anti-malarial drug artesunate blocks Wnt\/\u03b2-catenin pathway and inhibits growth, migration and invasion of uveal melanoma cells","volume":"18","author":"Zheng","year":"2018","journal-title":"Curr Cancer Drug Targets"},{"key":"B71","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/2141-9248.153609","article-title":"Anticancer effect of antimalarial artemisinin compounds","volume":"5","author":"Das","year":"2015","journal-title":"Ann Med Health Sci Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e42703","DOI":"10.1371\/journal.pone.0042703","article-title":"Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor-1","volume":"7","author":"Ba","year":"2012","journal-title":"PLoS ONE"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1007\/s10637-010-9481-8","article-title":"The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells","volume":"29","author":"Lu","year":"2011","journal-title":"Invest New Drugs"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14802\/jmd.14034","article-title":"Neurodegeneration with brain iron accumulation: diagnosis and management","volume":"8","author":"Hogarth","year":"2015","journal-title":"J Mov Disord"},{"key":"B75","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa020817","article-title":"Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome","volume":"348","author":"Hayflick","year":"2003","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.15252\/emmm.201606391","article-title":"Coenzyme A corrects pathological defects in human neurons of PANK2-associated neurodegeneration","volume":"8","author":"Orellana","year":"2016","journal-title":"EMBO Mol Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/nchembio.1906","article-title":"Extracellular 4'-phosphopantetheine is a source for intracellular coenzyme A synthesis","volume":"11","author":"Srinivasan","year":"2015","journal-title":"Nat Chem Biol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"6988","DOI":"10.1073\/pnas.0912105107","article-title":"Pantethine rescues a Drosophila model for pantothenate kinase-associated neurodegeneration","volume":"107","author":"Rana","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B79","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1007\/s12035-018-1333-0","article-title":"Pantothenate rescues iron accumulation in pantothenate kinase-associated neurodegeneration depending on the type of mutation","volume":"56","author":"\u00c1lvarez-C\u00f3rdoba","year":"2019","journal-title":"Mol Neurobiol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e10489","DOI":"10.15252\/emmm.201910489","article-title":"4\u2032-Phosphopantetheine corrects CoA, iron, and dopamine metabolic defects in mammalian models of PKAN","volume":"11","author":"Jeong","year":"2019","journal-title":"EMBO Mol Med"},{"key":"B81","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/B978-0-12-374105-9.00469-X","article-title":"Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP syndrome)","volume-title":"Encyclopedia of Movement Disorders","author":"Orrell","year":"2010"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1128\/JB.00334-11","article-title":"Pantethine rescues phosphopantothenoylcysteine synthetase and phosphopantothenoylcysteine decarboxylase deficiency in Escherichia coli but not in Pseudomonas aeruginosa","volume":"193","author":"Balibar","year":"2011","journal-title":"J Bacteriol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e0192028","DOI":"10.1371\/journal.pone.0192028","article-title":"Fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration: mechanism of action and efficacy in nonclinical models","volume":"13","author":"Elbaum","year":"2018","journal-title":"PLoS ONE"},{"key":"B84","doi-asserted-by":"publisher","first-page":"3247034","DOI":"10.1155\/2017\/3247034","article-title":"Open-label fosmetpantotenate, a phosphopantothenate replacement therapy in a single patient with atypical PKAN","volume":"2017","author":"Christou","year":"2017","journal-title":"Case Rep Neurol Med"},{"key":"B85","first-page":"1006","article-title":"A pilot study of a potential phosphopantothenate replacement therapy in 2 patients with pantothenate kinase-associated neurodegeneration","volume":"2","author":"Roa","year":"2017","journal-title":"Int J Rare Dis Orphan Drugs"},{"key":"B86","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/1740774519845673","article-title":"The fosmetpantotenate replacement therapy (FORT) randomized, double-blind, placebo-controlled pivotal trial: study design and development methodology of a novel primary efficacy outcome in patients with pantothenate kinase-associated neurodegeneration","volume":"16","author":"Klopstock","year":"2019","journal-title":"Clin Trials"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28392","article-title":"Fosmetpantotenate randomized controlled trial in pantothenate kinase associated neurodegeneration","author":"Klopstock","year":"2020","journal-title":"Mov Disord"},{"key":"B88","unstructured":"Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN2019"},{"key":"B89","unstructured":"7th International Symposium on NBIA & Related Disorders. Update on the CoA-Z Clinical Trial2020"},{"key":"B90","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/brain\/awt325","article-title":"Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model","volume":"137","author":"Brunetti","year":"2014","journal-title":"Brain"},{"key":"B91","doi-asserted-by":"publisher","first-page":"11260","DOI":"10.1038\/s41598-017-11564-8","article-title":"Acetyl-4\u2032-phosphopantetheine is stable in serum and prevents phenotypes induced by pantothenate kinase deficiency","volume":"7","author":"Di Meo","year":"2017","journal-title":"Sci Rep"},{"key":"B92","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13023-020-01530-5","article-title":"Pilot trial on the efficacy and safety of pantethine in children with pantothenate kinase-associated neurodegeneration: a single-arm, open-label study","volume":"15","author":"Chang","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B93","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1038\/s41467-018-06703-2","article-title":"A therapeutic approach to pantothenate kinase associated neurodegeneration","volume":"9","author":"Sharma","year":"2018","journal-title":"Nat Commun"},{"key":"B94","unstructured":"Choukri Ben Mamoun, PhD, Wins Best Presentation in Yale Lifesciences Pitchfest 20202021"},{"key":"B95","unstructured":"7th International Symposium on NBIA & Related Disorders. Status of PKAN Gene Therapy2020"},{"key":"B96","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10557-008-6132-9","article-title":"Phospholipase A2 biochemistry","volume":"23","author":"Burke","year":"2009","journal-title":"Cardiovasc Drugs Ther"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e1128616","DOI":"10.1080\/21675511.2015.1128616","article-title":"Mitochondrial dysfunction and defects in lipid homeostasis as therapeutic targets in neurodegeneration with brain iron accumulation","volume":"4","author":"Kinghorn","year":"2016","journal-title":"Rare Dis"},{"key":"B98","doi-asserted-by":"publisher","first-page":"20689","DOI":"10.1073\/pnas.1902958116","article-title":"Parkinson's disease-associated iPLA2-VIA\/PLA2G6 regulates neuronal functions and \u03b1-synuclein stability through membrane remodeling","volume":"116","author":"Mori","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3389\/fneur.2018.01100","article-title":"PLA2G6-Associated Neurodegeneration (PLAN): review of clinical phenotypes and genotypes","volume":"9","author":"Guo","year":"2018","journal-title":"Front Neurol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0022-510x(91)90208-o","article-title":"Neuroaxonal dystrophy in neuronal storage disorders: evidence for major GABAergic neuron involvement","volume":"104","author":"Walkley","year":"1991","journal-title":"J Neurol Sci"},{"key":"B101","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-020-01355-2","article-title":"The natural history of infantile neuroaxonal dystrophy","volume":"15","author":"Altuame","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1212\/01.wnl.0000327094.67726.28","article-title":"Neurodegeneration associated with genetic defects in phospholipase A(2)","volume":"71","author":"Gregory","year":"2008","journal-title":"Neurology"},{"key":"B103","article-title":"PLA2G6-associated neurodegeneration. 2008 Jun 19 [Updated 2017 Mar 23]","volume-title":"GeneReviews","author":"Gregory","year":""},{"key":"B104","unstructured":"Lipid peroxidation: chemical mechanism, biological implications and analytical determination\n            RepettoM\n            SemprineJ\n            BoverisA\n          IntechOpenLipid Peroxidation2012"},{"key":"B105","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3389\/fphys.2019.00641","article-title":"Deuterated polyunsaturated fatty acids reduce oxidative stress and extend the lifespan of C. elegans","volume":"10","author":"Beaudoin-Chabot","year":"2019","journal-title":"Front Physiol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/mds.27353","article-title":"Randomized, clinical trial of RT001: early signals of efficacy in Friedreich's ataxia","volume":"33","author":"Zesiewicz","year":"2018","journal-title":"Mov Disord"},{"key":"B107","unstructured":"AdamsD\n            DastgirJ\n            FloraC\n            MolinariRJ\n            HeerinckxF\n            MilnerPG\n          Case Report: Expanded Access Treatment of an Infantile Neuroaxonal Dystrophy (INAD) Patient with a Novel, Stabilized Polyunsaturated Fatty Acid Drug"},{"key":"B108","first-page":"1","volume-title":"Treatment of Infantile Neuroaxonal Dystrophy with RT001: A di-Deuterated Ethyl Ester of Linoleic Acid: Report of Two Cases","author":"Adams","year":"2020"},{"key":"B109","unstructured":"A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy2019"},{"key":"B110","unstructured":"7th International Symposium on NBIA & Related Disorders. Development and Progress of a Treatment Trial for Infantile Neuroaxonal Dystrophy with RT001D2020"},{"key":"B111","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cmet.2018.05.019","article-title":"Phospholipase PLA2G6, a parkinsonism-associated gene, affects Vps26 and Vps35, retromer function, and ceramide levels, similar to \u03b1-synuclein gain","volume":"28","author":"Lin","year":"2018","journal-title":"Cell Metab"},{"key":"B112","unstructured":"Desipramine in Infantile Neuroaxonal Dystrophy (INAD)2018"},{"key":"B113","volume-title":"Novel Therapeutic Strategies in NBIA: A Gene Therapy Approach for PLA2G6-Associated Neurodegeneration","author":"Whaler","year":"2018"},{"key":"B114","unstructured":"7th International Symposium on NBIA & Related Disorders. Therapeutic Approaches to Restore PLA2G6 Enzyme Function in INAD2020"},{"key":"B115","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40478-015-0221-3","article-title":"Neuropathology of Beta-propeller protein associated neurodegeneration (BPAN): a new tauopathy","volume":"3","author":"Paudel","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"B116","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1089\/ars.2013.5371","article-title":"An overview of autophagy: morphology, mechanism, and regulation","volume":"20","author":"Parzych","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"B117","doi-asserted-by":"publisher","first-page":"445-9","DOI":"10.1038\/ng.2562","article-title":"De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood","volume":"45","author":"Saitsu","year":"2013","journal-title":"Nat Genet"},{"key":"B118","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/15548627.2015.1047127","article-title":"The autophagy gene Wdr45\/Wipi4 regulates learning and memory function and axonal homeostasis","volume":"11","author":"Zhao","year":"2015","journal-title":"Autophagy"},{"key":"B119","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/15548627.2019.1630224","article-title":"WDR45 contributes to neurodegeneration through regulation of ER homeostasis and neuronal death","volume":"16","author":"Wan","year":"2020","journal-title":"Autophagy"},{"key":"B120","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Kim","year":"2011","journal-title":"Nat Cell Biol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"B122","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10295-016-1834-7","article-title":"An overview of rapamycin: from discovery to future perspectives","volume":"44","author":"Yoo","year":"2017","journal-title":"J Ind Microbiol Biotechnol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/gerona\/glw090","article-title":"Rapamycin: an InhibiTOR of aging emerges from the soil of Easter Island","volume":"71","author":"Arriola","year":"2016","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"B124","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrn3068","article-title":"Fighting neurodegeneration with rapamycin: mechanistic insights","volume":"12","author":"Bov\u00e9","year":"2011","journal-title":"Nat Rev Neurosci"},{"key":"B125","unstructured":"resTORbio Announces Initiation of Phase 1b\/2a Trial of RTB101 in Parkinson's Disease2019"},{"key":"B126","unstructured":"resTORbio Announces Initiation of Phase 1b\/2a Trial of RTB101 in Parkinson's Disease2019"},{"key":"B127","unstructured":"Research Identifies Several Possible Drug Candidates for Treating BPAN2020"},{"key":"B128","unstructured":"Study Sparks New Approach to BPAN Understanding and Treatment2020"},{"key":"B129","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ajhg.2011.09.007","article-title":"Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation","volume":"89","author":"Hartig","year":"2011","journal-title":"Am J Hum Genet"},{"key":"B130","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fgene.2015.00185","article-title":"Mutations of C19orf12, coding for a transmembrane glycine zipper containing mitochondrial protein, cause mis-localization of the protein, inability to respond to oxidative stress and increased mitochondrial Ca2+","volume":"6","author":"Venco","year":"2015","journal-title":"Front Genet"},{"key":"B131","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.bbabio.2013.10.015","article-title":"The endoplasmic reticulum-mitochondria connection: one touch, multiple functions","volume":"1837","author":"Marchi","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B132","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.gde.2016.04.006","article-title":"Mitochondria-associated ER membranes and Alzheimer disease","volume":"38","author":"Area-Gomez","year":"2016","journal-title":"Curr Opin Genet Dev"},{"key":"B133","doi-asserted-by":"publisher","first-page":"e89439","DOI":"10.1371\/journal.pone.0089439","article-title":"Impairment of Drosophila orthologs of the human orphan protein C19orf12 induces bang sensitivity and neurodegeneration","volume":"9","author":"Iuso","year":"2014","journal-title":"PLoS ONE"},{"key":"B134","doi-asserted-by":"publisher","first-page":"91","DOI":"10.15252\/emmm.201708361","article-title":"Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia","volume":"10","author":"Zanardi","year":"2018","journal-title":"EMBO Mol Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aba4624","article-title":"Antisense oligonucleotides for neurodegeneration","volume":"367","author":"Leavitt","year":"2020","journal-title":"Science"},{"key":"B137","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cell.2017.06.028","article-title":"Splicing-correcting therapy for SMA","volume":"170","author":"Wan","year":"2017","journal-title":"Cell"},{"key":"B138","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13023-018-0931-2","article-title":"Recommendations for the design of small population clinical trials","volume":"13","author":"Day","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B139","article-title":"RE-024, a phosphopantothenate replacement therapy for PKAN: mechanism of action and efficacy in nonclinical models","volume-title":"Proceedings of the ACMG Annual Clinical Genetics Meeting, March 2016","author":"Beconi","year":"2016"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.629414\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T12:40:50Z","timestamp":1618490450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.629414\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":139,"alternative-id":["10.3389\/fneur.2021.629414"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.629414","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"article-number":"629414"}}